Literature DB >> 20889918

Expression, cellular distribution, and prognostic relevance of TRAIL receptors in hepatocellular carcinoma.

Lydia Kriegl1, Andreas Jung, Jutta Engel, Rene Jackstadt, Alexander L Gerbes, Eike Gallmeier, Jana A Reiche, Heiko Hermeking, Antonia Rizzani, Christiane J Bruns, Frank T Kolligs, Thomas Kirchner, Burkhard Göke, Enrico N De Toni.   

Abstract

PURPOSE: After the advent of targeted therapies for hepatocellular carcinoma (HCC), much work is being done to provide a comprehensive description of the different signaling pathways contributing to cell survival and proliferation in this tumor. Apoptotic signaling mediated by tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) represents an important mechanism of tumor surveillance, but its importance in the development of HCC is not known. We thus investigated the cellular distribution and the prognostic importance of TRAIL receptors in HCC. EXPERIMENTAL
DESIGN: Immunohistochemical staining for TRAIL receptors was evaluated in HCC tissues and in matched surrounding nontumor tissues of 157 HCC patients treated with liver transplantation or partial hepatectomy. Survival was analyzed in 93 patients who underwent partial hepatectomy.
RESULTS: The fraction of HCC samples with positive membrane staining for TRAIL receptor 1 (TRAIL-R1) and 2 (TRAIL-R2) was 1.4- and 2.7-fold lower compared with that of hepatocytes from surrounding tissues (P = 0.01). Loss of either TRAIL-R1 or TRAIL-R2, as confirmed by a multivariate analysis, significantly worsened 5-year survival of HCC patients {survival, 27% versus 52% and 15% versus 43%; hazard ratio (HR), 2.3 [95% confidence interval (CI), 1.1-4.4] and 2.4 (95% CI, 1.1-5.2), respectively}. Loss of both TRAIL receptors further decreased survival of patients [HR, 5.72 (95% CI, 2.1-15.5) versus double-negative staining; P = 0.001], indicating an additive effect on survival of TRAIL-R1 and TRAIL-R2.
CONCLUSIONS: This pilot study suggests that loss of TRAIL receptors is a frequent feature of HCCs and an independent predictor of survival in patients undergoing partial hepatectomy. Future therapeutic protocols are likely to profit from the characterization of their expression and cellular distribution. Clin Cancer Res; 16(22); 5529-38. ©2010 AACR.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20889918     DOI: 10.1158/1078-0432.CCR-09-3403

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  22 in total

1.  High expression of CCL20 is associated with poor prognosis in patients with hepatocellular carcinoma after curative resection.

Authors:  Xiangjiu Ding; Kexin Wang; Hui Wang; Guangyong Zhang; Yajing Liu; Qingyun Yang; Weijie Chen; Sanyuan Hu
Journal:  J Gastrointest Surg       Date:  2011-11-10       Impact factor: 3.452

Review 2.  [In situ analyses of molecular mechanisms of colorectal carcinogenesis].

Authors:  L Kriegl
Journal:  Pathologe       Date:  2013-11       Impact factor: 1.011

Review 3.  Inflammation and liver tumorigenesis.

Authors:  Beicheng Sun; Michael Karin
Journal:  Front Med       Date:  2013-05-17       Impact factor: 4.592

Review 4.  Hepatocellular carcinoma: targeting of oncogenic signaling networks in TRAIL resistant cancer cells.

Authors:  Sundas Fayyaz; Ilhan Yaylim; Saime Turan; Sobia Kanwal; Ammad Ahmad Farooqi
Journal:  Mol Biol Rep       Date:  2014-07-19       Impact factor: 2.316

Review 5.  Death receptors as targets in cancer.

Authors:  O Micheau; S Shirley; F Dufour
Journal:  Br J Pharmacol       Date:  2013-08       Impact factor: 8.739

6.  Fibroblast growth factor receptor 1 as a putative therapy target in colorectal cancer.

Authors:  Friederike Göke; Antonia Göke; Anne von Mässenhausen; Alina Franzen; Rakesh Sharma; Robert Kirsten; Diana Böhm; Glen Kristiansen; Albrecht Stenzinger; Murry Wynes; Fred R Hirsch; Wilko Weichert; Lynn Heasley; Reinhard Buettner; Sven Perner
Journal:  Digestion       Date:  2013-10-17       Impact factor: 3.216

7.  TRAIL receptor I (DR4) polymorphisms C626G and A683C are associated with an increased risk for hepatocellular carcinoma (HCC) in HCV-infected patients.

Authors:  Christian Körner; Katarina Riesner; Benjamin Krämer; Marianne Eisenhardt; Andreas Glässner; Franziska Wolter; Thomas Berg; Tobias Müller; Tilman Sauerbruch; Jacob Nattermann; Ulrich Spengler; Hans Dieter Nischalke
Journal:  BMC Cancer       Date:  2012-03-08       Impact factor: 4.430

8.  Microsatellite instability, KRAS mutations and cellular distribution of TRAIL-receptors in early stage colorectal cancer.

Authors:  Lydia Kriegl; Andreas Jung; David Horst; Antonia Rizzani; Rene Jackstadt; Heiko Hermeking; Eike Gallmeier; Alexander L Gerbes; Thomas Kirchner; Burkhard Göke; Enrico N De Toni
Journal:  PLoS One       Date:  2012-12-20       Impact factor: 3.240

9.  Loss of TRAIL-receptors is a recurrent feature in pancreatic cancer and determines the prognosis of patients with no nodal metastasis after surgery.

Authors:  Eike Gallmeier; Dominik C Bader; Lydia Kriegl; Sabina Berezowska; Hendrik Seeliger; Burkhard Göke; Thomas Kirchner; Christiane Bruns; Enrico N De Toni
Journal:  PLoS One       Date:  2013-02-27       Impact factor: 3.240

10.  A New Player in the Development of TRAIL Based Therapies for Hepatocarcinoma Treatment: ATM Kinase.

Authors:  Venturina Stagni; Simonetta Santini; Daniela Barilà
Journal:  Cancers (Basel)       Date:  2012-04-05       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.